期刊
ARQUIVOS BRASILEIROS DE CARDIOLOGIA
卷 117, 期 4, 页码 750-763出版社
ARQUIVOS BRASILEIROS CARDIOLOGIA
DOI: 10.36660/abc.20200702
关键词
Pulmonary Arterial Hypertension; Pulmonary Hypertension; Diagnosis; Therapeutics
Advancements have been made in the treatment of PAH, with prognosis depending on accurate diagnosis and classification. Drug therapy is based on medications targeting different pathways, with a variety of formulations available. This review provides an overview of drug therapy strategies and the various forms and characteristics of PAH.
In the last decades, important advances have been made in the treatment of pulmonary arterial hypertension (PAH), a severe, progressive, incurable, and potentially fatal disease. For an adequate therapy, correct hemodynamic diagnosis and etiology classification are fundamental. Many etiologies - rheumatic disease, portal hypertension, congenital heart diseases, schistosomiasis - require specific measures, in addition to drug therapy for PAH. The specific therapy for PAH is based on medications that act on three pathophysiological pathways - prostacyclin, endothelin, and nitric oxide pathways. These drugs have multiple presentations (oral, intravenous, subcutaneous, and inhaled) and have changed the history of PAH. This review presents an overview of drug therapy strategies and different forms and peculiarities of PAH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据